These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26567863)

  • 21. Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents.
    Codner P; Bental T; Assali A; Vaknin-Assa H; Lev E; Kornowski R
    J Invasive Cardiol; 2014 Aug; 26(8):378-84. PubMed ID: 25091097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
    Tijssen RYG; Kraak RP; Lu H; Mifek JG; Carlyle WC; Donohoe DJ; De Winter RJ; Koch KT; Wykrzykowska JJ
    Expert Rev Med Devices; 2017 May; 14(5):325-334. PubMed ID: 28402204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
    de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Jüni P; Kastrati A; Windecker S
    Int J Cardiol; 2013 Oct; 168(6):5162-6. PubMed ID: 23993323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technical overview on the MiStent coronary stent.
    McCLAIN JB; Carlyle WC; Donohoe DJ; Ormiston JA
    Minerva Cardioangiol; 2016 Oct; 64(5):560-71. PubMed ID: 27152624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of drug-eluting stents.
    Räber L; Windecker S
    Cardiovasc Ther; 2011 Jun; 29(3):176-89. PubMed ID: 20370793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fully bioresorbable drug-eluting coronary scaffolds: A review.
    Charpentier E; Barna A; Guillevin L; Juliard JM
    Arch Cardiovasc Dis; 2015; 108(6-7):385-97. PubMed ID: 26113479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
    Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .
    Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ
    Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.